Neuroblastoma is characterized by a broad spectrum of clinical behavior, reflecting its biologic heterogeneity.7 A combination of clinical and biologic prognostic markers, including age, stage, MYCN status, ploidy, and histology, is used to classify risk and stratify treatment of patients with neuroblastoma. The gene discussed is MYCN; the disease is neuroblastoma.